IGC PHARMA, INC. (IGC) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
29/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseIGC / S&P 3.85% / 15.20% |
LoseIGC / S&P IGC unavailable / 15.00% |
LoseIGC / S&P IGC unavailable / 50.40% |
| 2026-Q10/3 |
LoseIGC / S&P -7.14% / -4.33% |
LoseIGC / S&P IGC unavailable / 11.30% |
LoseIGC / S&P IGC unavailable / 27.70% |
| 2025-Q40/3 |
LoseIGC / S&P -33.33% / 2.65% |
LoseIGC / S&P IGC unavailable / 9.00% |
LoseIGC / S&P IGC unavailable / 13.40% |
| 2025-Q31/3 |
WinIGC / S&P 35.48% / 8.12% |
LoseIGC / S&P -6.51% / 4.61% |
LoseIGC / S&P -55.56% / 13.45% |
| 2025-Q21/3 |
LoseIGC / S&P 10.71% / 10.94% |
WinIGC / S&P 24.95% / 4.83% |
LoseIGC / S&P -61.90% / 10.63% |
| 2025-Q10/3 |
LoseIGC / S&P -17.65% / -4.27% |
LoseIGC / S&P -5.50% / 4.98% |
LoseIGC / S&P IGC unavailable / 10.57% |
| 2024-Q40/3 |
LoseIGC / S&P -20.93% / 2.41% |
LoseIGC / S&P 1.64% / 5.25% |
LoseIGC / S&P IGC unavailable / 6.15% |
| 2024-Q30/3 |
LoseIGC / S&P 0.00% / 5.89% |
LoseIGC / S&P -11.98% / 5.89% |
LoseIGC / S&P IGC unavailable / 6.11% |
| 2024-Q21/3 |
WinIGC / S&P 7.50% / 4.28% |
LoseIGC / S&P -15.38% / 5.38% |
LoseIGC / S&P IGC unavailable / 5.12% |
| 2024-Q12/3 |
WinIGC / S&P 42.86% / 10.56% |
WinIGC / S&P 47.48% / 5.71% |
LoseIGC / S&P IGC unavailable / 5.59% |
| 2023-Q41/3 |
LoseIGC / S&P -22.22% / 11.69% |
WinIGC / S&P 60.00% / 6.81% |
LoseIGC / S&P IGC unavailable / 7.78% |
| 2023-Q32/3 |
WinIGC / S&P 16.13% / -3.27% |
WinIGC / S&P 135.79% / 7.52% |
LoseIGC / S&P IGC unavailable / -5.03% |
| 2023-Q21/3 |
LoseIGC / S&P -8.82% / 8.74% |
WinIGC / S&P 195.99% / 9.50% |
LoseIGC / S&P IGC unavailable / -8.57% |
| 2023-Q11/3 |
LoseIGC / S&P 6.25% / 7.50% |
WinIGC / S&P 215.57% / 10.77% |
LoseIGC / S&P IGC unavailable / -15.69% |
| 2022-Q41/3 |
LoseIGC / S&P -25.58% / 7.56% |
WinIGC / S&P 113.48% / 11.88% |
LoseIGC / S&P IGC unavailable / -17.99% |
| 2022-Q31/3 |
LoseIGC / S&P -18.87% / -4.88% |
WinIGC / S&P 77.02% / 13.47% |
LoseIGC / S&P IGC unavailable / -1.41% |
| 2022-Q20/3 |
LoseIGC / S&P -44.21% / -16.10% |
LoseIGC / S&P 8.44% / 13.71% |
LoseIGC / S&P IGC unavailable / 11.04% |
| 2022-Q11/3 |
WinIGC / S&P -3.06% / -4.60% |
LoseIGC / S&P -67.82% / 15.97% |
LoseIGC / S&P IGC unavailable / 42.23% |
| 2021-Q40/3 |
LoseIGC / S&P -33.78% / 11.03% |
LoseIGC / S&P -57.92% / 15.00% |
LoseIGC / S&P IGC unavailable / 96.40% |
| 2021-Q30/3 |
LoseIGC / S&P -9.76% / 0.58% |
LoseIGC / S&P -75.44% / 10.77% |
LoseIGC / S&P IGC unavailable / 69.42% |
| 2021-Q20/3 |
LoseIGC / S&P -8.38% / 8.55% |
LoseIGC / S&P -87.00% / 6.58% |
LoseIGC / S&P IGC unavailable / 51.81% |
| 2021-Q11/3 |
WinIGC / S&P 14.74% / 6.17% |
LoseIGC / S&P -77.95% / -1.06% |
LoseIGC / S&P IGC unavailable / 7.39% |
| 2020-Q41/3 |
WinIGC / S&P 50.00% / 12.15% |
LoseIGC / S&P -84.85% / -3.72% |
LoseIGC / S&P IGC unavailable / -33.42% |
| 2020-Q31/3 |
WinIGC / S&P 73.33% / 8.93% |
LoseIGC / S&P -79.18% / -2.04% |
LoseIGC / S&P IGC unavailable / -27.10% |
| 2020-Q21/3 |
WinIGC / S&P 22.45% / 20.54% |
LoseIGC / S&P -43.12% / -0.46% |
LoseIGC / S&P IGC unavailable / -27.11% |
| 2020-Q10/3 |
LoseIGC / S&P -22.22% / -19.60% |
LoseIGC / S&P -20.41% / 3.47% |
LoseIGC / S&P IGC unavailable / -14.75% |
| 2019-Q41/3 |
LoseIGC / S&P -35.05% / 9.07% |
WinIGC / S&P 18.43% / 5.36% |
LoseIGC / S&P IGC unavailable / 2.99% |
| 2019-Q31/3 |
LoseIGC / S&P -40.85% / 1.70% |
WinIGC / S&P 50.18% / 5.02% |
LoseIGC / S&P IGC unavailable / 0.21% |
| 2019-Q21/3 |
LoseIGC / S&P -21.15% / 4.30% |
WinIGC / S&P 46.17% / 6.64% |
LoseIGC / S&P IGC unavailable / 8.65% |
| 2019-Q12/3 |
WinIGC / S&P 642.86% / 13.65% |
WinIGC / S&P 133.40% / 8.12% |
LoseIGC / S&P IGC unavailable / 14.29% |
| 2018-Q41/3 |
LoseIGC / S&P -95.66% / -13.52% |
WinIGC / S&P 312.62% / 9.05% |
LoseIGC / S&P IGC unavailable / 18.23% |
| 2018-Q32/3 |
WinIGC / S&P 1216.33% / 7.71% |
WinIGC / S&P 564.78% / 10.21% |
LoseIGC / S&P IGC unavailable / 19.06% |
| 2018-Q21/3 |
LoseIGC / S&P -12.50% / 3.43% |
WinIGC / S&P 548.33% / 9.03% |
LoseIGC / S&P IGC unavailable / 14.46% |
| 2018-Q11/3 |
LoseIGC / S&P -44.00% / -0.76% |
WinIGC / S&P 176.25% / 7.68% |
LoseIGC / S&P IGC unavailable / 12.46% |
| 2017-Q41/3 |
WinIGC / S&P 177.78% / 6.64% |
LoseIGC / S&P -44.73% / 7.03% |
LoseIGC / S&P -33.33% / 13.82% |
| 2017-Q30/3 |
LoseIGC / S&P -12.20% / 4.48% |
LoseIGC / S&P -78.27% / 5.68% |
LoseIGC / S&P -57.14% / 17.57% |
| 2017-Q20/3 |
LoseIGC / S&P -12.77% / 3.09% |
LoseIGC / S&P -88.37% / 4.83% |
LoseIGC / S&P -56.25% / 17.74% |
| 2017-Q11/3 |
WinIGC / S&P 67.86% / 6.07% |
LoseIGC / S&P -87.54% / 3.67% |
LoseIGC / S&P -58.82% / 13.32% |
| 2016-Q40/3 |
LoseIGC / S&P -39.13% / 3.82% |
LoseIGC / S&P -71.50% / 2.09% |
LoseIGC / S&P -33.33% / 7.05% |
| 2016-Q30/3 |
LoseIGC / S&P -11.54% / 3.85% |
LoseIGC / S&P -66.68% / 0.20% |
LoseIGC / S&P -33.33% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | IGC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -23.26% | 20.78% |
| Annualized return | -23.26% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | IGC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -79.50% | 83.14% |
| Annualized return | -27.17% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | IGC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -21.43% | 319.30% |
| Annualized return | -2.38% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |